PTU-063 Faecal calprotectin – time to re-draw the line

IntroductionFaecal calprotectin (FCP) is a useful investigation for supporting a diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) (1). The cut off for a positive result remains controversial and has a significant impact on prompting invasive procedures and use of health care resources (2). We reviewed the impact of a local IBS/IBD pathway on patient outcomes and sought an evidence based threshold for a positive FCP result.MethodWe reviewed the FCP requests sent by primary care physicians in Barking, Havering and Redbridge University Trust (BHRUT) from November 2015 to March 2016. BHRUT uses a quantitative fluorescence enzyme immunoassay (FEIA); EliA Calprotectin 2. Initial thresholds for negative and indeterminate FCP results were set at